Daniel Burg1, Aryeh Babkoff1, Omer Or2, Noam Olshinka2, Jonathan Abraham Demma3, Mohamad Adila1,3, Marc Wygoda4, Philip Blumenfeld4, Judith Diment5, Masha Galiner6, Yusef Azraq6, Daniela Katz1,7, Petachia Reissman8, Sadie Ostrowicki9, Gabriella Sebbag10, Narmine Elkhateeb1,11, Anat Hershko Moshe1,11, Dania Jaber1,11, Adi Hollander1,11, Limor Rubin1,11, Aviad Zick1,12,*
Oncology Research, DOI:10.32604/or.2026.070233
Abstract Background: —Synovial sarcoma is a rare soft tissue sarcoma. Treatment of synovial sarcoma includes surgery, radiation, pazopanib, and chemotherapy. Targeted therapies, such as B-Raf proto-oncogene, serine/threonine kinase (BRAF) inhibitors, are emerging as a potential treatment option. We describe the sixth case of a BRAFV600E synovial sarcoma, the first extra-thoracic case. This case is the first to show a complete pathological response to BRAF & mitogen-activated protein kinase kinase (MEK) inhibitors. Case description: —We treated a 22-year-old male with a left groin BRAFV600E synovial sarcoma with doxorubicin, Ifosphamide & Sodium 2-Mercaptoethanesulfonate. When we identified BRAFV600E in the tumor,… More >